Shots: The approval is based on P-I/II CheckMate -040 study assessing Opdivo (1 mg/kg, IV) + Yervoy (3 mg/kg, IV) q3w for four doses, followed by Opdivo (240mg, q2w) in […]readmore
Tags : (ipilimumab)
Shots: The US FDA has accepted sBLA for the dual regimen as 1L treatment for metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations and has granted […]readmore
Shots: The companies have submitted the sBLA for the combination therapy to expand its use as 1L treatment of unresectable, advanced/ recurrent NSCLC in Japan, for a partial change in […]readmore
Shots: The P-III CheckMate -915 study involves assessing of Opdivo (240mg, IV, q2w) in combination with Yervoy (1 mg/kg, q6w) vs Opdivo (480mg, q4w) as monothx. as the adjuvant therapy […]readmore
Shots: The US FDA has accepted sBLA and granted BT designation for the dual regimen to treat patients with advanced HCC prior treated with sorafenib. The sBLA ha also received […]readmore
Shots: The P-III CheckMate -9LA study involve assessing of Opdivo (360mg q3w) + Yervoy (1mg/kg q6w) combined with CT (two cycles) vs CT as monothx. (up to four cycles followed […]readmore
Shots: The P-III CheckMate -227 Part 1a study involves assessing of Opdivo + Yervoy vs platinum-doublet CT in patients with 1L advanced NSCLC across non-squamous and squamous tumor expressing PD-L1 […]readmore
Shots: The P-II CheckMate -650 trial involves assessing of Opdivo (nivolumab, 1mg/kg) + Yervoy (ipilimumab, 3mg/kg) in patients with mCRPC P-II study result in asymptomatic or minimally symptomatic patients & […]readmore
Shots: The P-III CheckMate-214 study involves assessing of Opdivo (nivolumab, 3mg/kg) + Yervoy (ipilimumab,1mg/kg) vs sunitinib (50mg qd @4wks.) in patients with previously untreated advanced or metastatic renal cell carcinoma […]readmore
Shots: The approval is based on P-III CheckMate-214 study results assessing Opdivo (3mg/kg) + low-dose Yervoy(1mg/kg) vs sunitinib (50mg, qd) in patients with previously untreated advance RCC P-III Checkmate-214 study […]readmore